Collaboration with Third Parties. 24.1 Nothing contained in this agreement shall prevent either Xxxxx or Lagerwall, individually or jointly with their respective research teams, to conduct research relating to FLC technology in collaboration with third parties.
Collaboration with Third Parties. Ionis may engage one or more academic or non-profit institutions to conduct work under any Collaboration Program Research Plan or Development Plan or to conduct drug discovery activities to identify a High Interest Target Development Candidate pursuant to Section 2.3; provided, however, that (a) with respect to any such academic or non-profit institution engaged to conduct such activities with respect to a Collaboration Target, where such engagement occurs after the date such Collaboration Target is designated, or (b) with respect to any such academic or non-profit institution engaged to conduct such activities with respect to one of the remaining High Interest Targets, where such engagement occurs after the later of [***] or the date such High Interest Target is designated, (i) prior to engaging such academic or non-profit institution to conduct such activities, Ionis will consult with Biogen in good faith with respect to the terms of any agreement or amendment to an existing agreement to be entered into with such institution and consider Biogen’s comments with respect thereto in good faith and (ii) if Ionis enters into any such agreement or amendment on terms objected to by Biogen in a written notice provided to Ionis prior to the execution thereof, it shall promptly so notify Biogen, which notice will include a copy of such agreement or amendment, and within [***] days following Biogen’s receipt of such notice, Biogen may elect to replace the applicable High Interest Target or Collaboration Target with a different gene target in accordance with the procedures set forth in Section 1.3.2 or Section 1.4.2, as applicable, and such replacement will not be counted for purposes of determining whether Biogen has exceeded the Replacement Limit or Substitution Limit, as applicable.
Collaboration with Third Parties. In certain circumstances the holiday residence may call on third parties to provide medical and paramedical care. These medical and paramedical services call under the professional liability of the care providers themselves, and will also be invoiced directly by them to the customer. In this respect the holiday residence serves as only as a coordinator and cannot be held liable for these services.
Collaboration with Third Parties. Genentech may at any time and in its sole discretion collaborate with or otherwise jointly develop an Indication with an Ex-U.S. Genentech Partner in the Genentech Territory. In addition, for Permitted Indications, XOMA may collaborate with an Ex-U.S. Genentech Partner with respect to only the development of such Permitted Indications. Further, in the event that Genentech does not opt-in to a Future Indication or Organ Transplant Indication by the end of a successful Phase III Clinical Trial as provided in Section 5.4(d), and does not exercise its Right of Prohibition under Section 5.2, XOMA may enter into agreements for the promotion of Licensed Product for such Indications in the Co-Promotion Territory with Third Party providers of sales and/or marketing services as long as such Third Parties provide such services only in the Co-Promotion Territory and the Third Parties are not one of the top twenty-five (25) largest biotechnology or pharmaceutical companies, as meas- ured by sales revenues from pharmaceutical product sales ("Contract Sales Organizations"). Neither this Section 5.9 nor any other provision in this Agreement is intended to grant XOMA any rights to use, sell, offer for sale, make or import Licensed Product in the Genentech Territory. For purposes of clarity, this section is not intended to create or otherwise address Genentech's manufacturing obligations which are set forth in Article 9.
Collaboration with Third Parties. During the term of this Agreement, SELECT and its Affiliates will not directly develop or assist a Third Party in developing a Vaccine Product that targets a Target Disease of a Licensed Product where such Vaccine Product would be directly competitive with the Licensed Product.
